StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3036% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Cost of sales by Year

Cost of sales — Product manufacturing, logistics & write-downs (ex-royalties, $M) ($M)

Vertex Pharmaceuticals Cost of sales: $602M in FY2025, up 16.5% from a year earlier.

Latest, FY2025
602
Period ended Dec 31, 2025
Change on a year earlier
+16.5%
516 in FY2024
History
4 years
Since FY2022
Sources
2
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-Q / 10-K Note (Segment Reporting — Significant Segment Expenses).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedCost of sales — Product manufacturing, logistics & write-downs (ex-royalties, $M) ($M)Year on yearSource
FY2025Dec 31, 2025602+16.5%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 2024516+47.9%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 2023349+34.0%Form 10-K (filed 2026-02-13) ↗
FY2022Dec 31, 2022261–Form 10-K (filed 2025-02-13) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Cost of sales ($M), annual FY2022–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/seg-cogs-product

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.